Quinazoline-based human phosphodiesterase 5 inhibitors exhibited a selective vasorelaxant effect on rat isolated pulmonary arteries involving NO-sGC-cGMP pathway and calcium inhibitory effects

Simple item page
dc.contributor.authorUsana Chatturong
dc.contributor.authorH�l�ne Martin
dc.contributor.authorPerle Totoson
dc.contributor.authorKornkanok Ingkaninan
dc.contributor.authorPrapapan Temkitthawon
dc.contributor.authorSaharat Sermsenaphorn
dc.contributor.authorThanachon Somarin
dc.contributor.authorAdchatawut Konsue
dc.contributor.authorM Paul Gleeson
dc.contributor.authorC�line Demougeot
dc.contributor.authorKrongkarn Chootip
dc.date.accessioned2025-07-21T06:07:43Z
dc.date.issued2022-09-24
dc.identifier.doi10.1016/j.vph.2022.107111
dc.identifier.urihttps://dspace.kmitl.ac.th/handle/123456789/11681
dc.subjectSodium nitroprusside
dc.subject.classificationPulmonary Hypertension Research and Treatments
dc.titleQuinazoline-based human phosphodiesterase 5 inhibitors exhibited a selective vasorelaxant effect on rat isolated pulmonary arteries involving NO-sGC-cGMP pathway and calcium inhibitory effects
dc.typeArticle

Files

Collections

All